SOD1 and amyotrophic lateral sclerosis: Based on the groundbreaking effects observed in rodents, a randomized, double-blind, placebo-controlled Phase 1/2 study (VALOR; NCT02623699) was launched to assess the pharmacokinetics and tolerability of intrathecal administration of tofersen in patients with familial ALS who have SOD1 gene mutations [78].